|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer Statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, Sawyers CL and Scher HI: Targeting
the androgen receptor pathway in prostate cancer. Curr Opin
Pharmacol. 8:440–448. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zarour L and Alumkal J: Emerging therapies
in Castrate-resistant prostate cancer. Curr Urol Rep. 11:152–158.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang HT, Yao YH, Li BG, Tang Y, Chang JW
and Zhang J: Neuroendocrine prostate cancer (NEPC) progressing from
conventional prostatic adenocarcinoma: Factors associated with time
to development of NEPC and survival from NEPC diagnosis-a
systematic review and pooled analysis. J Clin Oncol. 32:3383–3390.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lotan TL, Gupta NS, Wang W, Toubaji A,
Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo
AM, et al: ERG gene rearrangements are common in prostatic small
cell carcinomas. Mod Pathol. 24:820–828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan HL, Sood A, Rahimi HA, Wang W, Gupta
N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, et al: Rb
loss is characteristic of prostatic small cell neuroendocrine
carcinoma. Clin Cancer Res. 20:890–903. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Robinson D, Van Allen EM, Wu YM, Schultz
N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC,
Attard G, et al: Integrative clinical genomics of advanced prostate
cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beltran H, Prandi D, Mosquera JM, Benelli
M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV,
Varambally S, et al: Divergent clonal evolution of
castration-resistant neuroendocrine prostate cancer. Nat Med.
22:298–305. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schneiderman J, London WB, Brodeur GM,
Castleberry RP, Look AT and Cohn SL: Clinical significance of MYCN
amplification and ploidy in favorable-stage neuroblastoma: A report
from the Children's Oncology Group. J Clin Oncol. 26:913–918. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Massimino M, Biassoni V, Gandola L, Garrè
ML, Gatta G, Giangaspero F, Poggi G and Rutkowski S: Childhood
medulloblastoma. Crit Rev Oncol Hematol. 105:35–51. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Northcott PA, Jones DT, Kool M, Robinson
GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P,
Taylor MD and Pfister SM: Medulloblastomics: The end of the
beginning. Nat Rev Cancer. 12:818–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bjerke L, Mackay A, Nandhabalan M, Burford
A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, et al:
Histone H3.3. Mutations drive pediatric glioblastoma through
upregulation of MYCN. Cancer Discov. 3:512–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Swartling FJ, Savov V, Persson AI, Chen J,
Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, et
al: Distinct neural stem cell populations give rise to disparate
brain tumors in response to N-MYC. Cancer Cell. 21:601–613. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fielitz K, Althoff K, De Preter K,
Nonnekens J, Ohli J, Elges S, Hartmann W, Klöppel G, Knösel T,
Schulte M, et al: Characterization of pancreatic glucagon-producing
tumors and pituitary gland tumors in transgenic mice overexpressing
MYCN in hGFAP-positive cells. Oncotarget. 7:74415–74426. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu Y, Xu L, Chang Y, Zeng T, Chen X, Wang
A, Groth J, Foo WC, Liang C, Hu H and Huang J: N-Myc promotes
therapeutic resistance development of neuroendocrine prostate
cancer by differentially regulating miR-421/ATM pathway. Mol
Cancer. 18:112019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hanker LC, Karn T, Holtrich U, Graeser M,
Becker S, Reinhard J, Ruckhäberle E, Gevensleben H and Rody A:
Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer.
Anticancer Res. 33:371–377. 2013.PubMed/NCBI
|
|
20
|
Hashimoto Y, Skacel M and Adams JC: Roles
of fascin in human carcinoma motility and signaling: Prospects for
a novel biomarker? Int J Biochem Cell Biol. 37:1787–1804. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scott KL, Nogueira C, Heffernan TP, van
Doorn R, Dhakal S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, et
al: Proinvasion metastasis drivers in Early-stage melanoma are
oncogenes. Cancer Cell. 20:92–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li A, Morton JP, Ma Y, Karim SA, Zhou Y,
Faller WJ, Woodham EF, Morris HT, Stevenson RP, Juin A, et al:
Fascin is regulated by slug, promotes progression of pancreatic
cancer in mice, and is associated with patient outcomes.
Gastroenterology. 146:1386–1396.e17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barnawi R, Al-Khaldi S, Majed Sleiman G,
Sarkar A, Al-Dhfyan A, Al-Mohanna F, Ghebeh H and Al-Alwan M:
Fascin is critical for the maintenance of breast cancer stem cell
pool predominantly via the activation of the notch Self-renewal
pathway. Stem Cells. 34:2799–2813. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun J, He H, Xiong Y, Lu S, Shen J, Cheng
A, Chang WC, Hou MF, Lancaster JM, Kim M and Yang S: Fascin protein
is critical for transforming growth factor β Protein-induced
invasion and filopodia formation in Spindle-shaped tumor cells. J
Biol Chem. 286:38865–38875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Snyder M, Huang XY and Zhang JJ: Signal
transducers and activators of transcription 3 (STAT3) directly
regulates cytokine-induced fascin expression and is required for
breast cancer cell migration. J Biol Chem. 286:38886–38893. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao X, Gao S, Ren H, Sun W, Zhang H, Sun
J, Yang S and Hao J: Hypoxia-inducible factor-1 promotes pancreatic
ductal adenocarcinoma invasion and metastasis by activating
transcription of the actin-bundling protein fascin. Cancer Res.
74:2455–2464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sandelin A, Wasserman WW and Lenhard B:
ConSite: Web-based prediction of regulatory elements using
cross-species comparison. Nucleic Acids Res. 32:W249–W252. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beltran H, Rickman DS, Park K, Chae SS,
Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, et
al: Molecular characterization of neuroendocrine prostate cancer
and identification of new drug targets. Cancer Discov. 1:487–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dardenne E, Beltran H, Benelli M, Gayvert
K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, et
al: N-Myc induces an EZH2-mediated transcriptional program driving
neuroendocrine prostate cancer. Cancer Cell. 30:563–577. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JK, Phillips JW, Smith BA, Park JW,
Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG,
Mathis C, et al: N-myc drives neuroendocrine prostate cancer
initiated from human prostate epithelial cells. Cancer Cell.
29:536–547. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Beltran H: The N-myc Oncogene: Maximizing
its targets, regulation, and therapeutic potential. Mol Cancer Res.
12:815–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adams JC: Roles of fascin in cell adhesion
and motility. Curr Opin Cell Biol. 16:590–596. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin S, Huang C, Gunda V, Sun J, Chellappan
SP, Li Z, Izumi V, Fang B, Koomen J, Singh PK, et al: Fascin
controls metastatic colonization and mitochondrial oxidative
phosphorylation by remodeling mitochondrial actin filaments. Cell
Rep. 28:2824–2836.e8. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Darnel AD, Behmoaram E, Vollmer RT, Corcos
J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA and Bismar
TA: Fascin regulates prostate cancer cell invasionand is associated
with metastasis and biochemical failurein prostate cancer. Cin
Cancer Res. 15:1376–1383. 2009. View Article : Google Scholar
|
